Declines and downward pressure on Agenus (AGEN) stock are primarily tied to the inherent financial challenges faced by clinical-stage biotechnology enterprises. As a pre-revenue or early-commercialization developer of complex immuno-oncology drugs, the company relies heavily on ongoing research and development spending, which translates to continuous operating cash burn. Market sell-offs are frequently triggered by secondary equity offerings that dilute existing shareholders, capital-raising dilution risks, clinical trial delays, or broader risk-off sentiment hitting speculative micro-cap equities.